Literature DB >> 10969041

Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats.

A Vieillard-Baron1, E Frisdal, S Eddahibi, I Deprez, A H Baker, A C Newby, P Berger, M Levame, B Raffestin, S Adnot, M P d'Ortho.   

Abstract

Chronic hypoxic pulmonary hypertension (PH) results from persistent vasoconstriction, excess muscularization, and extracellular matrix remodeling of pulmonary arteries. The matrix metalloproteinases (MMPs) are a family of proteinases implicated in extracellular matrix turnover and hence in smooth muscle and endothelial cell migration and proliferation. Because MMP expression and activity are increased in PH, we designed the present study to investigate whether inhibition of lung MMPs in rats subjected to chronic hypoxia (CH) contributes to or protects against vascular remodeling and PH. To achieve lung MMP inhibition, rats exposed to 10% O(2) for 15 days were treated with either doxycycline (20 mg/kg per day by gavage starting 2 days before and continuing throughout the CH period) or a single dose of recombinant adenovirus (Ad) for the human tissue inhibitors of metalloproteinases-1 (hTIMP-1) gene (Ad.hTIMP-1, 10(8) plaque-forming units given intratracheally 2 days before CH initiation). Control groups either received no treatment or were treated with an adenovirus containing no gene in the expression cassette (Ad.Null). Efficacy of hTIMP-1 gene transfer was assessed both by ELISA on bronchoalveolar lavages and by hTIMP-1 immunofluorescence on lung sections. MMP inhibition in lungs was evaluated by in situ zymography and gelatinolytic activity assessment using [(3)H]gelatin. Rats treated with either doxycycline or Ad.hTIMP-1 had higher pulmonary artery pressure and right heart ventricular hypertrophy more severe than their respective controls. Worsening of PH was associated with increased muscularization and periadventitial collagen accumulation in distal arteries. In conclusion, our study provides compelling evidence that MMPs play a pivotal role in protecting against pulmonary artery remodeling.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969041     DOI: 10.1161/01.res.87.5.418

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  25 in total

1.  Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function: the MESA-RV Study.

Authors:  Steven M Kawut; R Graham Barr; W Craig Johnson; Harjit Chahal; Harikrishna Tandri; Aditya Jain; Michael R Bristow; Jorge R Kizer; Emilia Bagiella; Joao A C Lima; David A Bluemke
Journal:  Biomarkers       Date:  2010-10-05       Impact factor: 2.658

Review 2.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; John C Marecki; Amy Richter; Iwona Fijalkowska; Sonia Flores
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

3.  Possible involvement of Cyclic-GMP-dependent protein kinase on matrix metalloproteinase-2 expression in rat aortic smooth muscle cells.

Authors:  Nupur B Dey; Thomas M Lincoln
Journal:  Mol Cell Biochem       Date:  2012-05-23       Impact factor: 3.396

4.  Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells.

Authors:  Todd M Bull; Christina A Meadows; Christopher D Coldren; Mark Moore; Sylk M Sotto-Santiago; Serge P Nana-Sinkam; Thomas B Campbell; Mark W Geraci
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-27       Impact factor: 6.914

5.  Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension.

Authors:  Zeenat Safdar; Emilio Tamez; Wenyaw Chan; Basant Arya; Yimin Ge; Anita Deswal; Biykem Bozkurt; Adaani Frost; Mark Entman
Journal:  JACC Heart Fail       Date:  2014-07-09       Impact factor: 12.035

Review 6.  Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.

Authors:  Y Y Li; A M Feldman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9.

Authors:  Manoj M Lalu; Cindy Q Gao; Richard Schulz
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

8.  Morphometric analysis of the lung vasculature after extracorporeal membrane oxygenation treatment for pulmonary hypertension in newborns.

Authors:  Arno van Heijst; Remco Haasdijk; Freek Groenman; Frans van der Staak; Christina Hulsbergen-van de Kaa; Ronald de Krijger; Dick Tibboel
Journal:  Virchows Arch       Date:  2004-06-03       Impact factor: 4.064

9.  TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice.

Authors:  Andrew D Frutkin; Goro Otsuka; April Stempien-Otero; Casilde Sesti; Liang Du; Mia Jaffe; Helén L Dichek; Caroline J Pennington; Dylan R Edwards; Madeline Nieves-Cintrón; Daniel Minter; Michael Preusch; Jie Hong Hu; Julien C Marie; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03-26       Impact factor: 8.311

10.  CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation.

Authors:  Na Li; De-Zai Dai; Yin Dai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.